10x Genomics, Inc. (TXG)

Market Cap	2.60B
Revenue (ttm)	641.81M
Net Income (ttm)	-76.32M
Shares Out	126.55M
EPS (ttm)	-0.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,891,610
Open	19.94
Previous Close	19.80
Day's Range	19.50 - 20.73
52-Week Range	6.78 - 21.18
Beta	2.18
Analysts	Hold
Price Target	15.61 (-23.93%)
Earnings Date	Feb 11, 2026

About TXG

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as ...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Sep 12, 2019
• Employees: 1,306
• Stock Exchange: NASDAQ
• Ticker Symbol: TXG
• Website: https://www.10xgenomics.com

Financial Performance

In 2024, 10x Genomics's revenue was $610.79 million, a decrease of -1.28% compared to the previous year's $618.73 million. Losses were -$182.63 million, -28.41% less than in 2023.

Analyst Summary

According to 14 analysts, the average rating for TXG stock is "Hold." The 12-month stock price target is $15.61, which is a decrease of -23.93% from the latest price.

Price Target

$15.61

(-23.93% downside)

Analyst Consensus: Hold